Sophie Lanzkron, M.D., M.H.S.
Work in the Sophie Lanzkron Lab is focused on understanding the barriers to care for adults with sickle cell disease. Our research has shown that despite the approval of hydroxyurea treatment predicted to decrease hospitalizations for sickle cell disease patients' the cost of care has increased significantly in recent years. Research is ongoing to identify the factors that limit access to care for this population.
Research Areas: sickle cell diseases, patient-centered health care, hydroxyurea, health services research